laboratori corpor america hold
diagnost tool
larg lab pressur lh lower guid
implic lower pt
larg lab pressur think magnitud move lh
today overdon lh morn lower top bottom line guid cite
slower growth direct-to-consum genet test come
surpris us lower referr volum hospit health system volum declin
certain health plan longer exclus lh
advers weather order impact lh lower guid come day lab rival
quest buy lower guid larg differ reason
seen investor day recal downgrad lh follow
challeng today updat affirm view variou challeng mark lh
lower estim pt use multipl
lower adj ep
guid driven dx segment lh lower total revenu growth
guid midpoint vs prior
street lh lower dx segment revenu guid
midpoint vs prior project lh lower adj ep
today guid come week
call lh lower revenu dx adj ep guid
setup call lh character challeng lose exclus
larg contract face greater cut pama effect jan lh expect
guid call indic expect modest growth adj
ep inclus capit deploy lh expect growth covanc
comment core diagnost busi grow lh conced
aggress target account ahead
impact lab rival quest lower guid yesterday mainli due
revenu accrual account also call bad weather hurrican michael
california wildfir recent east coast snowstorm cite weak
ancestri dtc busi also indic yesterday alreadi win new
physician custom lh affirm view lh net share loser
least end perhap longer think possibl
send-out lab like ghdx possibl could see modest impact
weather though typic weather impact larg shrug
lab offset higher demand elsewher
readthrough lower revenu lh could mean lower revenu
 buy howev also suspect custom
ancestri ilmn-form helix could take share thu could
off-set dip believ helix exome-sequenc solut may
increasingli reson given stronger clinic util exom sequenc vs array
genotyp view
readthrough lh indic slower expect dtc consum test
referr help us understand buy set low bar
molecular collect saw explos growth page
labcorp lead refer laboratori test
compani also oper covanc drug develop
chiltern
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
model updat lower revenu y/i
look revenu growth continu
look covanc revenu y/i lower adj ep
y/i y/i trim revenu
y/i trim adj ep y/i
commentari quest investor day yesterday effect januari
quest becom in-network lab provid unitedhealthcar anthem horizon
anthem georgia add access million new live quest size increas
health plan revenu opportun mainli net share gain lh
assum share revenue opportun time begun reach
physician unit network use lh in-network
lab alreadi win new custom identifi reach
high-util account believ repres revenu opportun fulli
convert quest within account identifi account
consid quest loyalist like shift major lab provid
remain account mix provid use along lh
lab continu court quest initi target short-term
high-util account later pursu addit medium-term
account repres compani see revenu opportun
/aet quest size increas health plan revenu opportun mainli
net share gain lh assum share revenue opportun
time expect share shift gradual howev unclear much
quickli competitor busi shift side recal lh today deriv
lab rev
readthrough deliv solid beat guid us
street cite moder growth larg custom
like better job plan order throughout year previous cite
guid conserv look realist us despit today news
lh continu believ volum nice y/i thu
reason doubt molecular collect busi meet goal
solid double-digit think could mean y/i said
comment relat think possibl helix ancestri might
take share thu sinc benefit
three provid share shift among materi impact either
case lower revenu would biggest impact
lh sinc lh access test
hold unchang target price novemb
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price novemb
diagnost tool
laboratori corpor america hold
hold unchang target price novemb
diagnost tool
laboratori corpor america hold
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin novemb et
date time product novemb et
laboratori corpor america hold lh
price target lh appli multipl adj ep estim assum modest earn
per share growth project think mid-point lower end rang warrant compani expect achiev
slower top bottom line growth rel histor rang opinion
price target roll forward multipl adj ep estim assum view
modest earn growth project believ potenti faster top-lin growth accret capit
deploy would mark upsid ep estim
pt use multipl adj ep estim
price target base multipl revenu estim discount three year discount
risk achiev target price valuat
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
hold unchang target price novemb
diagnost tool
laboratori corpor america hold
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
